Arnold Silva
Nephrology · Meridian, IDNPI 1497790646
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $411,538 of the $625,501 with a category attached, or 65.8%. It is spread thinly across 28 manufacturers, the largest accounting for just 19.7%. Among nephrology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 972 payments — averaging $643.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$123K
- Bayer$115K
- Travere Therapeutics, Inc.$91K
- GSK$52K
- Lilly USA, LLC$45K
- Amgen$44K
- plus $156K from 22 others
Across 1,063 payments — averaging $2310.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$607K
- GSK$431K
- Travere Therapeutics, Inc.$284K
- Boehringer Ingelheim$275K
- Vertex$196K
- AstraZeneca$136K
- plus $528K from 15 others
What the payments were for
- Consulting fees$83,68913%
- Speaking & faculty fees$411,53866%
- Travel & lodging$103,68117%
- Food & beverage$26,5224%
- Education$710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 193 | $123,080 |
| Bayer | 120 | $115,122 |
| Travere Therapeutics, Inc. | 202 | $90,829 |
| GSK | 83 | $51,563 |
| Lilly USA, LLC | 37 | $45,076 |
| Amgen(2 entities) | 81 | $43,563 |
| Boehringer Ingelheim | 45 | $37,876 |
| Aurinia Pharma U.S., Inc. | 36 | $30,742 |
| Apellis Pharmaceuticals, Inc. | 21 | $20,527 |
| Vifor Pharma, Inc. | 29 | $19,914 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $7,012 |
| Novartis | 23 | $6,983 |
| OPKO Pharmaceuticals, LLC | 14 | $5,321 |
| Akebia Therapeutics Inc | 4 | $4,986 |
| Fresenius USA Marketing, Inc. | 4 | $4,541 |
| Eli Lilly | 2 | $4,500 |
| Calliditas Therapeutics US Inc. | 20 | $3,944 |
| Boehringer Ingelheim International GmbH | 13 | $3,672 |
| Johnson & Johnson | 6 | $2,729 |
| Ardelyx, Inc. | 7 | $2,692 |
| Otsuka America Pharmaceutical, Inc. | 14 | $543 |
| Sanofi | 2 | $150 |
| Sobi, Inc | 1 | $36 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Genentech, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $18 |
| AbbVie | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$625,501 in reported general payments places this provider in the 95th percentile of 30 nephrology providers in Idaho.
Other nephrology in Meridian
- Liang WuMeridian$386K
- Mary DittrichMeridian$7K
- Kevin MitchellMeridian$679
- Amanda HallMeridian$354
- Jerry MengMeridian$274
- Amit SharmaMeridian$252
- Aaron FeardayMeridian$198
- Robert DavidsonMeridian$108
- Shaun JoshiHayden$5K
- Heidi JoistNampa$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.